Lilly’s Emgality nabs third-to-market migraine nod, but aims to be 'treatment of choice' in CGRP

Eli Lilly may not be first to market in the CGRP field, but an exec says a few factors in its Emgality launch will help the company beat its rivals. With Thursday’s FDA approval, Lilly will soon find out.